OPTN News and Press, OptiNose Inc. From 11/07/20

OptiNose, Inc. (OPTN) Q3 2020 Results Conference Call November 05, 2020 08:00 AM ET Company Participants Jonathan Neely - Vice President, Investor Relations Peter Miller - Chief Executive Officer Ramy Mahmoud - President and Chief Operating Officer Vic Clavelli - Chief Commercial Officer Keit...

Image source: The Motley Fool. OptiNose, Inc. (NASDAQ: OPTN) Q3 2020 Earnings Call Nov 7, 2020 , 8:00 p.m. ET Operator Continue reading For further details see: OptiNose, Inc. (OPTN) Q3 2020 Earnings Call Transcript

The following slide deck was published by OptiNose, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: OptiNose, Inc. 2020 Q3 - Results - Earnings Call Presentation

OptiNose (OPTN): Q3 GAAP EPS of -$0.43 beats by $0.06.Revenue of $15.44M (+24.5% Y/Y) beats by $0.04M.Press Release For further details see: OptiNose EPS beats by $0.06, beats on revenue

Company reports third quarter 2020 XHANCE net revenue of $15.4 million New prescriptions of XHANCE increased 23% from second quarter 2020 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Optinose...

Ever-Glory International (EVK) +115%.Align Technology (ALGN) +27% on Q3 results.Bio-Path Holdings (BPTH) +24%. onHelix Energy Solutions Group (HLX) +16% on Q3 results.OptiNose (OPTN) +14% on preliminary Q3 results.KBS Fashion Group (KBSF) +14%.Marathon Patent Gro...

Optinose (OPTN) up 17% premarket on reporting preliminary XHANCE net revenue growth of 78% Y/Y and 50% Q/Q to $15.4M in Q3 vs. consensus of $13.9M. Q3 results will be out on November 5, 2020. CEO Peter Miller said “By exceeding the third quarter 2020 ...

Preliminary X HANCE Net Revenue G rowth of 78% C ompared to Third Quarter 2019 and 50% C ompared to Second Quarter 2020 Conference C all and W ebcast to be held November 5, 2020 at 8:00 a.m. Eastern Time YARDLEY, Pa., Oct...

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays Improvement was observed across a broad range of measures including multiple symptoms and both general and disease-specific quality of li...

YARDLEY, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) --   Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and busine...